Leonard Shultz to Drug Synergism
This is a "connection" page, showing publications Leonard Shultz has written about Drug Synergism.
Connection Strength
0.085
-
de Groot AP, Saito Y, Kawakami E, Hashimoto M, Aoki Y, Ono R, Ogahara I, Fujiki S, Kaneko A, Sato K, Kajita H, Watanabe T, Takagi M, Tomizawa D, Koh K, Eguchi M, Ishii E, Ohara O, Shultz LD, Mizutani S, Ishikawa F. Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia. EBioMedicine. 2021 Feb; 64:103235.
Score: 0.045
-
Moriceau G, Ory B, Mitrofan L, Riganti C, Blanchard F, Brion R, Charrier C, Battaglia S, Pilet P, Denis MG, Shultz LD, M?nkk?nen J, R?dini F, Heymann D. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res. 2010 Dec 15; 70(24):10329-39.
Score: 0.022
-
Evans R, Shultz LD, Dranoff G, Fuller JA, Kamdar SJ. CSF-1 regulation of Il6 gene expression by murine macrophages: a pivotal role for GM-CSF. J Leukoc Biol. 1998 Dec; 64(6):810-6.
Score: 0.010
-
Rajan TV, Shultz LD, Babu S, Doukas J, Greiner D, Porte P. Diethylcarbamazine (DEC) does not induce nitric oxide (NO) synthesis. Exp Parasitol. 1998 Mar; 88(3):217-22.
Score: 0.009